The Comparison Study of Intralesional Botulinum Toxin A and Corticosteroid Injection for Alopecia Areata
Status:
Unknown status
Trial end date:
2013-02-01
Target enrollment:
Participant gender:
Summary
Alopecia areata is one of the most common cause of non-scarring alopecia. The pathogenesis is
still unclear, however, it is believed to be an autoimmune disease. This disease is not a
life-threatening condition but it has a significant psychological impact to patient's quality
of life.
Many triggers have been proposed such as viral infection, stress and neurologic factors.
There are many studies show the correlation between disease activities and neurotransmitters
level. Substance P and calcitonin gene-related peptide play major role in early stage of
disease. These substances cause imbalance of CD4/CD8 lymphocyte in pathologic site and loss
of immune privilege of hair follicles.
The conventional treatment of alopecia areata with intralesional corticosteroid injection
might treat the end of pathogenesis process.
There is no therapeutic intervention for the origin of disease. Fortunately, botulinum toxin
A could be a novel treatment of alopecia areata. The botulinum toxin A demonstrates
inhibition release of substance P in many publications.
To sum up, the treatment of alopecia areata with intralesional corticosteroid injection still
be a standard treatment, nevertheless, patients have to receive this treatment every month
until regrowth of scalp hair. Corticosteroid injection have several side effects, for
example, skin atrophy, pigmentary change and hypothalamic-pituitary-adrenal axis suppression.
Moreover, injection pain is also affect to psychological aspect .
This study purpose is to evaluate the efficacy of botulinum toxin A for alopecia areata and
reduce corticosteroid side effects, as well as, others opportunity cost. There is no
prospective, randomized-controlled trial of comparison study between botulinum toxin A
injection and corticosteroid injection for alopecia areata, therefore, investigators conduct
this study for the greatest benefit to alopecia areata patients and for the future research
in disease etiology.
Phase:
N/A
Details
Lead Sponsor:
Siriraj Hospital
Treatments:
abobotulinumtoxinA Botulinum Toxins Botulinum Toxins, Type A incobotulinumtoxinA onabotulinumtoxinA Triamcinolone Triamcinolone Acetonide Triamcinolone diacetate Triamcinolone hexacetonide